Newly Diagnosed Multiple Myeloma clinical trials

Explore recruiting newly diagnosed multiple myeloma clinical trials.

Recruiting newly diagnosed multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Newly Diagnosed Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, open-label, multicenter multi-cohort study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple myeloma

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - IFM2021-01

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide - A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom)

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma

Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Newly Diagnosed Multiple Myeloma trials by city

Newly Diagnosed Multiple Myeloma in Toronto Newly Diagnosed Multiple Myeloma in Vancouver Newly Diagnosed Multiple Myeloma in Montreal Newly Diagnosed Multiple Myeloma in Calgary Newly Diagnosed Multiple Myeloma in Edmonton Newly Diagnosed Multiple Myeloma in Ottawa Newly Diagnosed Multiple Myeloma in Winnipeg Newly Diagnosed Multiple Myeloma in Quebec City Newly Diagnosed Multiple Myeloma in Hamilton Newly Diagnosed Multiple Myeloma in Kitchener Newly Diagnosed Multiple Myeloma in London Newly Diagnosed Multiple Myeloma in Halifax Newly Diagnosed Multiple Myeloma in New York Newly Diagnosed Multiple Myeloma in Los Angeles Newly Diagnosed Multiple Myeloma in Chicago Newly Diagnosed Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease